TY - JOUR T1 - A ketogenic supplement improves white matter energy supply and processing speed in mild cognitive impairment JF - medRxiv DO - 10.1101/2021.03.18.21253884 SP - 2021.03.18.21253884 AU - Maggie Roy AU - Mélanie Fortier AU - François Rheault AU - Manon Edde AU - Etienne Croteau AU - Christian-Alexandre Castellano AU - Francis Langlois AU - Valérie St-Pierre AU - Bernard Cuenoud AU - Christian Bocti AU - Tamas Fulop AU - Maxime Descoteaux AU - Stephen C. Cunnane Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/20/2021.03.18.21253884.abstract N2 - INTRODUCTION White matter (WM) energy supply is crucial for axonal function and myelin maintenance. Providing ketones, the brain’s alternative fuel to glucose, is a therapeutic strategy to bypass the brain’s glucose-specific energy deficit in mild cognitive impairment (MCI). How an additional supply of ketones affects glucose or ketone uptake in specific WM fascicles in MCI has not previously been described.METHODS This 6-month interventional study included MCI participants randomized to a placebo (n = 16) or ketogenic medium chain triglyceride (kMCT; n = 17) drink. A neurocognitive battery and brain imaging were performed pre- and post-intervention. WM fascicle uptake of ketone and glucose and structural properties were assessed using positron emission tomography and diffusion imaging, respectively.RESULTS Ketone uptake was increased by 2.5 to 3.2-fold in nine fascicles of interest (P < 0.001) only in the kMCT group, an effect seen both in deep WM and in fascicle cortical endpoints. Improvement in processing speed was associated with WM ketone uptake globally and in individual fascicles, most importantly the fornix (r = +0.61; P = 0.014).DISCUSSION A 6-month ketogenic supplementation in MCI improved WM energy supply globally. The significant positive association with processing speed suggests that ketones may have a role in myelin integrity in MCI.Competing Interest StatementSCC has consulted for or received travel honoraria or test products from Nestle Health Science, Bulletproof, Cerecin, and Abitec. SCC is the founder and director of the consulting company, Senotec Ltd. MD is CSO and shareholder of Imeka Solutions Inc (www.imeka.ca) and MR is consultant for Imeka Solutions Inc.Clinical TrialNCT02551419Funding StatementFinancial support for the BENEFIC trial was provided by the Alzheimer Association USA (PCTR-15-328047), FRQS (FR40072), and University of Sherbrooke. MR was funded by MITACS and Nestle Health Science. The University of Sherbrooke Institutional Chair in Neuroinformatics also provided funding support. Abitec provided the kMCT (Captex 355) and placebo oil. The intervention drinks for both arms were prepared under contract at INAF, University Laval, Quebec, QC, Canada.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional ethical committee (CIUSSS de l Estrie CHUS Sherbrooke Quebec Canada).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOriginal data and processed data will be made available upon request. All processing steps and results can be reproduced using the TractoFlow pipeline.ADAlzheimer’s diseaseMCImild cognitive impairmentWMwhite matterkMCTketogenic medium chain triglycerideApoE4apolipoprotein E4MMSEMini-Mental State ExaminationMoCAMontreal Cognitive Assessment scoreMRImagnetic resonance imagingDTIdiffusion tensor imagingCSFcerebrospinal fluidWMHwhite matter hyperintensitiesPETpositron emission tomographyFDG18F-flurodeoxyglucoseAcAc11C-acetoacetateβ-HBbeta-hydroxybutyratePCCposterior cingulate segment of the cingulumPHCparahippocampal segment of the cingulumFXfornixAFarcuate fasciculusCC2genu of the corpus callosumCC7splenium of the corpus callosumIFOFinferior fronto-occipital fasciculusILFinferior longitudinal fasciculusUFuncinate fasciculus ER -